ライフサイエンスコーパス: invasive bladder cancer

1 on markers and novel therapeutic targets for invasive bladder cancer.

2 gnature to predict progression in non-muscle-invasive bladder cancer.

3 tential prognostic and therapeutic value for invasive bladder cancer.

4 romboxane synthase (TXAS) gene expression in invasive bladder cancer.

5 emains the gold standard for treating muscle-invasive bladder cancer.

6 cal mainstay for the treatment of non-muscle-invasive bladder cancer.

7 ed significant independent associations with invasive bladder cancer.

8 ectomy remains the gold-standard therapy for invasive bladder cancer.

9 cial component of the surgical management of invasive bladder cancer.

10 current radiotherapy in patients with muscle-invasive bladder cancer.

11 ion of severe dysplasia/carcinoma in situ to invasive bladder cancer.

12 upport the aggressive surgical management of invasive bladder cancer.

13 five cystectomy specimens from patients with invasive bladder cancer.

14 t effective therapy for high-risk non-muscle-invasive bladder cancer.

15 f life of patients undergoing cystectomy for invasive bladder cancer.

16 apy over radical cystectomy alone for muscle-invasive bladder cancer.

17 and BM staining as prognostic indicators in invasive bladder cancer.

18 servation in the management of patients with invasive bladder cancer.

19 ve harnessed for the treatment of non-muscle-invasive bladder cancer.

20 ent and the protocol for treating non-muscle invasive bladder cancer.

21 tment of both non-muscle-invasive and muscle-invasive bladder cancer.

22 Calmette-Guerin (BCG)-experienced non-muscle-invasive bladder cancer.

23 dvanced solid malignancies, including muscle-invasive bladder cancer.

24 ade nonmuscle-invasive and high-grade muscle-invasive bladder cancer.

25 ineligible patients with cT2-4aN0-1M0 muscle-invasive bladder cancer.

26 -1 inhibitor, in BCG-unresponsive non-muscle-invasive bladder cancer.

27 onal character found in patients with muscle-invasive bladder cancer.

28 edanib or placebo in locally advanced muscle-invasive bladder cancer.

29 for cisplatin-eligible patients with muscle-invasive bladder cancer.

30 in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

31 d survival evaluated in patients with muscle invasive bladder cancer.

32 in approximately 40% of patients with muscle-invasive bladder cancer.

33 hemotherapy and radical treatment for muscle-invasive bladder cancer.

34 of recurrence and progression of non-muscle-invasive bladder cancer.

35 enefits to anti-PD-1 treatment in non-muscle invasive bladder cancer.

36 of pathological complete response in muscle-invasive bladder cancer.

37 or cisplatin-ineligible patients with muscle-invasive bladder cancer.

38 lity therapy for select patients with muscle-invasive bladder cancer.

39 elective bladder-sparing treatment of muscle-invasive bladder cancer.

40 spheroids derived from patients with muscle-invasive bladder cancer.

41 red from toenails and the risk of non-muscle invasive bladder cancer.

42 motherapy on response and survival in muscle-invasive bladder cancer.

43 in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

44 change management of patients with nonmuscle invasive bladder cancer.

45 NAs to help evaluate patients with nonmuscle invasive bladder cancer.

46 ladder preservation for patients with muscle invasive bladder cancer.

47 urrent use with radiotherapy to treat muscle-invasive bladder cancer.

48 ve the cure rates of patients diagnosed with invasive bladder cancer.

49 podia of angiogenic endothelial tip cells in invasive bladder cancer.

50 hemotherapy regimen for patients with muscle invasive bladder cancer.

51 h metastatic disease in patients with muscle-invasive bladder cancer.

52 native to cystectomy in patients with muscle-invasive bladder cancer.

53 ical therapy for BCG-unresponsive non-muscle-invasive bladder cancer.

54 verall survival after radical cystectomy for invasive bladder cancer.

55 cystectomy or radiotherapy alone, for deeply invasive bladder cancer.

56 tcome as first-line adjunctive treatment for invasive bladder cancer.

57 from controls and also nonmuscle from muscle-invasive bladder cancer.

58 tcomes and quality of life for patients with invasive bladder cancer.

59 ection (PLND) is the preferred treatment for invasive bladder cancer.

60 u (CIS), the precursor lesion of most muscle-invasive bladder cancers.

61 atment for localized and regionally advanced invasive bladder cancers.

62 resented both superficial bladder tumors and invasive bladder cancers.

63 inoma (mUC), and as high as 80% in nonmuscle invasive bladder cancers.

64 ers, and (3) PGDH is completely lost in most invasive bladder cancers.

65 Of 432 newly evaluated patients with muscle-invasive bladder cancer, 151 were treated by standard ra

66 Non-muscle invasive bladder cancer, a disease with the oldest immun

67 s or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncol

68 vival in patients who undergo cystectomy for invasive bladder cancer and are node-negative.

69 its applicability in case studies of muscle-invasive bladder cancer and essential thrombocythemia.

70 is the cornerstone treatment for non-muscle-invasive bladder cancer and intravesical therapy can fur

71 This suggests that ASS1 loss occurs in invasive bladder cancer and is targetable by ADI-PEG 20.

72 ve been identified in up to 15-20% of muscle-invasive bladder cancer and metastatic urothelial carcin

73 fered to all suitable candidates with muscle-invasive bladder cancer and not only to patients with si

74 receptor I (IGF-IR) is up-regulated in human invasive bladder cancer and promotes migration and invas

75 nts completing combined-modality therapy for invasive bladder cancer and retaining their native bladd

76 ant role in non-invasive than that in muscle-invasive bladder cancer and suggest that cohesin complex

77 he definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from

78 on definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore not included

79 ing intermediate, were present in high-grade invasive bladder cancers and associated with more freque

80 el to help predict progression of non-muscle-invasive bladder cancers and delineate a systematic, gen

81 marker in 81% of human high-grade nonmuscle invasive bladder cancers and used as a target for the de

82 mainstay definitions of high-risk nonmuscle invasive bladder cancer are based on grade and stage.

83 Trials in nonmuscle-invasive bladder cancer are evaluating the role of immun

84 Muscle-invasive bladder cancers are characterized by their dist

85 aring many of the genetic features of muscle-invasive bladder cancers, are classified as non-muscle-i

86 oma of the urinary bladder (a model of human invasive bladder cancer) as well as adjacent normal tiss

87 ell, and squamous cell carcinoma subtypes of invasive bladder cancer, as well as in T24, J82, and UM-

88 Invasive bladder cancer (BC) is one of the most lethal m

89 for muscle-invasive and high-risk nonmuscle-invasive bladder cancer (BCa), but is associated with si

90 Muscle invasive bladder cancers (BCs) can be divided into 2 maj

91 Our work highlights aspects of muscle-invasive bladder cancer biology associated with clinical

92 ign and interpretation of clinical trials in invasive bladder cancer but also help to identify and op

93 surgery achieve similar cure rates in muscle-invasive bladder cancer, but the choice of which treatme

94 we created a novel transgenic mouse model of invasive bladder cancer by targeting an active dimerized

95 lease of cytochrome c into the cytosol in an invasive bladder cancer cell line T24.

96 ubstrate (HA)-gel technique, showed that the invasive bladder cancer cell lines secrete elevated leve

97 proteome of the RT4 non-invasive and HT1197 invasive bladder cancer cell lines was identified and in

98 eport a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA

99 servation with radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accru

100 In selected patients with muscle-invasive bladder cancer, combined-modality therapy (tran

101 ectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit

102 Half of patients with muscle-invasive bladder cancer develop metastatic disease, and

103 Remarkably, invasive bladder cancer driven by active Stat3 was predo

104 Patients with clinical T2-4aN0/XM0 muscle-invasive bladder cancer eligible for RC were enrolled.

105 Non-muscle-invasive bladder cancer embraces a spectrum of tumors wi

106 kers may have prognostic value in non-muscle invasive bladder cancer for guiding optimal treatment of

107 Human invasive bladder cancer frequently develops without prio

108 itulates this unique clinical progression of invasive bladder cancer has not yet been developed.

109 umors, several histopathological subtypes of invasive bladder cancer have been identified as being mo

110 Patients with locally 'advanced' or muscle invasive bladder cancer have higher mortality rates than

111 tment for patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) is tumor resection fo

112 High-risk, nonmuscle invasive bladder cancer (HR-NMIBC) represents a costly a

113 High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous dis

114 he management of both superficial and muscle-invasive bladder cancer in the last 5 years.

115 dder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant

116 No patient progressed to muscle-invasive bladder cancer in this trial.

117 In contrast, for invasive bladder cancer, incidence was more strongly ele

118 Muscle-invasive bladder cancer is a disease of older individual

119 Low-grade non-muscle invasive bladder cancer is a specific category of bladde

120 Radical TUR for muscle-invasive bladder cancer is a successful bladder-sparing

121 n increasingly common malignancy, and muscle invasive bladder cancer is associated with particularly

122 gimen for patients with nonmetastatic muscle-invasive bladder cancer is not defined.

123 Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bl

124 cystectomy and urinary diversion for muscle invasive bladder cancer), kidney surgery (nephrectomy, d

125 cantly associated with progression to muscle-invasive bladder cancer (log-rank test; P < 0.001) in th

126 Molecular imaging of muscle-invasive bladder cancer (MBC) is restricted to its locor

127 In invasive bladder cancer, meticulous extended LND offers

128 ded to accurately stage patients with muscle-invasive bladder cancer (MIBC) and metastatic urothelial

129 Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on hist

130 During progression, luminal muscle-invasive bladder cancer (MIBC) can transition to the agg

131 The current treatment paradigm for muscle-invasive bladder cancer (MIBC) consists of cisplatin-bas

132 Muscle-invasive bladder cancer (MIBC) generally responds poorly

133 Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis.

134 The treatment of muscle-invasive bladder cancer (MIBC) has evolved substantially

135 their urinary bladder despite having muscle-invasive bladder cancer (MIBC) has sparked years of rese

136 omy (RC) for definitive management of muscle-invasive bladder cancer (MIBC) in current clinical guide

137 Muscle-invasive bladder cancer (MIBC) is a heterogeneous diseas

138 the immune microenvironment of cancer.Muscle-invasive bladder cancer (MIBC) is a potentially lethal d

139 Muscle-invasive bladder cancer (MIBC) is an aggressive disease

140 In humans, muscle-invasive bladder cancer (MIBC) is highly aggressive and

141 r, clinical response in patients with muscle-invasive bladder cancer (MIBC) is limited, with only 20-

142 The standard of care treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy, wh

143 Muscle-invasive bladder cancer (MIBC) represents 25% of newly d

144 e method of assessing the response of muscle-invasive bladder cancer (MIBC) to neoadjuvant treatment

145 adiation is debated for patients with muscle-invasive bladder cancer (MIBC) undergoing curative-inten

146 o radical cystectomy for treatment of muscle-invasive bladder cancer (MIBC), but biomarkers are neede

147 ystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering.

148 ing trials of neoadjuvant therapy for muscle-invasive bladder cancer (MIBC), identifying opportunitie

149 is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-based, blad

150 g combined-modality therapy (CMT) for muscle-invasive bladder cancer (MIBC), reserving cystectomy for

151 In muscle-invasive bladder cancer (MIBC), the evidence shows compa

152 ne-excluded syngeneic mouse models of muscle-invasive bladder cancer (MIBC), we show that platinum-ba

153 t important predictors of survival in muscle-invasive bladder cancer (MIBC).

154 d low survival rates in patients with muscle-invasive bladder cancer (MIBC).

155 he standard of care for patients with muscle-invasive bladder cancer (MIBC).

156 chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC).

157 my (RC) is standard for patients with muscle-invasive bladder cancer (MIBC).

158 gnostically significant in high-grade muscle-invasive bladder cancer (MIBC).

159 no such advance has been achieved in muscle-invasive bladder cancer (MIBC).

160 chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequen

161 , noninvasive urothelial lesions, and muscle-invasive bladder cancers (MIBC) from 22 patients.

162 Muscle-invasive bladder cancers (MIBCs) are biologically hetero

163 For muscle-invasive bladder cancers (MIBCs), TURBT may delay defini

164 For muscle-invasive bladder cancer, multimodal treatment involving

165 Comparison with muscle-invasive bladder cancer mutation profiles revealed lower

166 In muscle-invasive bladder cancer, neoadjuvant studies have focuse

167 ) patients received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after induction, three h

168 dder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence r

169 Once diagnosed, patients with nonmuscle invasive bladder cancer (NMIBC) are committed to a lifet

170 pose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to

171 tions for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are needed.

172 rexpression of fibulin-3 in T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitative reverse

173 The grading of non-muscle invasive bladder cancer (NMIBC) continues to face challe

174 care for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for several decades.

175 PURPOSE OF REVIEW: As high-risk nonmuscle invasive bladder cancer (NMIBC) has a high propensity to

176 It has long been recognized that non-muscle-invasive bladder cancer (NMIBC) has a low propensity (20

177 Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent tu

178 Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer

179 Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extre

180 The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by larg

181 Non-muscle-invasive bladder cancer (NMIBC) is the most common type

182 The standard treatment of nonmuscle invasive bladder cancer (NMIBC) is transurethral resecti

183 Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) often have recurrence or

184 ion of EV mRNA markers to monitor non-muscle invasive bladder cancer (NMIBC) recurrence after TURBT.

185 The management of nonmuscle invasive bladder cancer (NMIBC) recurrent after bacillus

186 Non-muscle-invasive bladder cancer (NMIBC) remains one of the most

187 Management of high-risk non-muscle-invasive bladder cancer (NMIBC) represents a clinical ch

188 mic profiling of premalignant and non-muscle invasive bladder cancer (NMIBC) that ensued in the chemi

189 mited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence

190 with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) without carcinoma in sit

191 the current standard of care for non-muscle-invasive bladder cancer (NMIBC), but recurrence is commo

192 dies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle

193 cancer is primarily diagnosed as non-muscle-invasive bladder cancer (NMIBC), with high recurrence an

194 andard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC).

195 first-line therapy for high-risk non-muscle-invasive bladder cancer (NMIBC).

196 tly the recommended treatment for non-muscle-invasive bladder cancer (NMIBC).

197 l treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC).

198 and progression in patients with non-muscle-invasive bladder cancer (NMIBC).

199 bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer (NMIBC).

200 in the diagnosis and management of nonmuscle invasive bladder cancer (NMIBC).

201 nge was associated with lower odds of muscle-invasive bladder cancer (odds ratio [OR], 0.91; 95% CI,

202 a 1:1 ratio, patients with localized muscle-invasive bladder cancer of clinical stage T2 (confined t

203 omprised genes frequently affected in muscle-invasive bladder cancer of nonpapillary origin, focusing

204 isease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assess

205 sponse rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assesse

206 In summary, these data support a model of invasive bladder cancer pathogenesis in which both the p

207 1, an aggressive cisplatin-resistant muscle-invasive bladder cancer patient-derived xenograft (PDX)

208 nalysis provides prognostic value for muscle invasive bladder cancer patients and a better model fit

209 labelled whole slide images from 100 muscle invasive bladder cancer patients.

210 primary bladder tumor samples from 30 muscle-invasive bladder cancer patients.

211 stigation of TAR-200 in patients with muscle-invasive bladder cancer planned for radical cystectomy.

212 re, we profile the global proteome of muscle-invasive bladder cancers pre- and post-neoadjuvant chemo

213 For muscle-invasive bladder cancer, radical cystectomy with neoadju

214 nagement strategies for low-grade non-muscle invasive bladder cancer rely heavily on routine office c

215 year survival rates for patients with muscle-invasive bladder cancer remain suboptimal.

216 PURPOSE OF REVIEW: Nonmuscle invasive bladder cancer represents a large majority of p

217 -12-82 GG polymorphisms were associated with invasive bladder cancer risk [odds ratio (OR), 2.60; 95%

218 diplotypes were associated with overall and invasive bladder cancer risk.

219 eatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy

220 We observed that invasive bladder cancer specimens had significantly redu

221 agnosed with histologically confirmed muscle-invasive bladder cancer (stage cT2-cT4 N0M0), had an Eas

222 Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be

223 For muscle-invasive bladder cancer, systemic perioperative chemothe

224 ations are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: a

225 evels were higher in plasma of patients with invasive bladder cancer than healthy individuals.

226 so shown to localize to the nucleus of human invasive bladder cancers that were primarily composed of

227 For non-muscle-invasive bladder cancer, the mainstay of treatment is co

228 In patients with non-muscle invasive bladder cancer, the standard immunotherapy invo

229 py for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for mus

230 l role in the unique clinical progression of invasive bladder cancer through the CIS pathway.

231 nstrated that the IGF-IR is overexpressed in invasive bladder cancer tissues and promotes motility an

232 nstrated that the IGF-IR is overexpressed in invasive bladder cancer tissues compared with nonmaligna

233 tio, cisplatin-eligible patients with muscle-invasive bladder cancer to receive neoadjuvant durvaluma

234 e randomly assigned 360 patients with muscle-invasive bladder cancer to undergo radiotherapy with or

235 n frozen tumor samples from 42 patients with invasive bladder cancer treated by cystectomy with monoc

236 overall survival among patients with muscle-invasive bladder cancer undergoing radical cystectomy an

237 ectomy, among patients with localized muscle-invasive bladder cancer undergoing radical cystectomy is

238 monotherapy for treating high-risk nonmuscle invasive bladder cancer unresponsive to bacillus Calmett

239 in cisplatin-ineligible patients with muscle-invasive bladder cancer, warranting additional study as

240 emotherapy does benefit patients with muscle-invasive bladder cancer, we reviewed all phase II and II

241 Patients with cT2-4a muscle-invasive bladder cancer were randomly assigned to FCT or

242 s of ET-1 are higher in patients with muscle-invasive bladder cancers, which are associated with high

243 in patients with BCG-unresponsive non-muscle-invasive bladder cancer who declined or were ineligible

244 ologic reports from 268 patients with muscle-invasive bladder cancer who received radical cystectomy.

245 s with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or decli

246 in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS).

247 les of blood vascular endothelium from human invasive bladder cancer with normal bladder tissue, we f

248 nd had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-gra

249 er is the highest risk subtype of non-muscle-invasive bladder cancer with unpredictable outcome and p

250 The management of nonmuscle invasive bladder cancer with variant histology is challe

251 ture, which effectively distinguishes muscle-invasive bladder cancer with worse clinical prognosis fr

252 lysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and

253 er is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable prognosis,

254 ajor treatment modality used to treat muscle-invasive bladder cancer, with patient outcomes similar t

255 bladder epithelial HCV29 cells versus highly invasive bladder cancer YTS1 cells, both derived from tr